Wart Remover

Description

The product is identified by SPL code 34089-3 and is presented as a white to off-white, round, biconvex tablet, which is debossed with "A" on one side and "123" on the opposite side. Each tablet contains 500 mg of Acetaminophen as the active ingredient. The formulation includes several inactive ingredients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol, iron oxide red, and iron oxide yellow.

Uses and Indications

This drug is indicated for the removal of common warts.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed with warm water and dried thoroughly prior to application. Using an applicator, such as a brush, one drop of the medication should be applied at a time to ensure sufficient coverage of the wart. It is important to allow the medication to fully absorb and dry after application.

This procedure may be repeated once or twice daily as needed, for a maximum duration of up to 2 weeks.

Contraindications

Use is contraindicated in patients with the following conditions or situations:

• Application on irritated skin or wounds.

• Application on any area that is infected or reddened.

• Use on moles, skin tags, birthmarks, or warts with hair growing from them.

• Application on genital warts or warts located on the face or mucous membranes.

These contraindications are established to prevent potential adverse effects associated with the application in these specific conditions.

Warnings and Precautions

For external use only. It is imperative to avoid contact with the eyes. In the event of accidental exposure to the eyes, the affected area should be flushed with water for a minimum of 15 minutes. Additionally, inhalation of vapors should be strictly avoided to prevent respiratory irritation.

In cases of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Healthcare professionals should advise patients to discontinue use and consult a physician if irritation occurs, if the condition worsens or fails to improve, or if discomfort persists. Monitoring for these symptoms is essential to ensure patient safety and effective management of any adverse reactions.

Side Effects

Patients using this product should be aware that it is intended for external use only. Adverse reactions may include irritation at the site of application. In some cases, patients may experience a worsening of their condition or may find that their symptoms do not improve. Additionally, if discomfort persists, it is advised that patients discontinue use and consult a healthcare professional.

Drug Interactions

There are no specific drug interactions or laboratory test interactions identified in the available data. Therefore, no dosage adjustments or monitoring recommendations are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Wart Remover (elp essential wart removal). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, it is crucial to seek medical assistance or contact a Poison Control Center immediately.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

The safety of this product during pregnancy has not been established. This product is contraindicated in pregnancy due to potential risks to the fetus. Pregnant patients or those planning to become pregnant should consult a healthcare provider before use to discuss potential risks and benefits.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or its effects on lactation. Additionally, no data are provided concerning the excretion of this medication in breast milk or its potential effects on breastfed infants. Healthcare professionals should consider the lack of information when advising lactating mothers about the use of this medication.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved. Common symptoms of overdose may include, but are not limited to, respiratory depression, altered mental status, cardiovascular instability, and gastrointestinal disturbances.

In the event of an overdose, immediate medical intervention is recommended. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Furthermore, it is crucial to consult local poison control centers or toxicology experts for guidance on specific management protocols tailored to the substance involved. Continuous assessment and supportive measures should be prioritized to ensure patient safety and mitigate potential complications associated with overdose.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children to prevent accidental ingestion or exposure. Instruct patients that if the product comes into contact with the eyes, they should flush the eyes with water for at least 15 minutes and seek medical attention if irritation persists.

In the event of accidental ingestion, patients should be informed to seek medical help or contact a Poison Control Center immediately. It is important to emphasize the need to avoid inhaling vapors from the product, as this may lead to respiratory discomfort.

Patients should also be counseled to cap the bottle tightly after use and store it at room temperature, away from heat sources, to maintain product integrity. If any discomfort persists after using the product, patients should be encouraged to consult their doctor for further evaluation and guidance.

Storage and Handling

The product is supplied in various configurations, with specific NDC numbers available for identification. It should be stored at room temperature, ideally between 20 and 25°C (68 to 77°F). Care should be taken to avoid exposure to excessive heat, which may compromise the integrity of the product.

To ensure optimal preservation, it is essential to tighten the cap securely after each use. Additionally, users are advised to avoid inhaling any vapors that may be released during handling. Proper adherence to these storage and handling guidelines will help maintain the product's efficacy and safety.

Additional Clinical Information

The medication is administered topically, with the recommended application being one drop at a time to adequately cover the wart. It is important for patients to allow the solution to fully absorb and dry before reapplying. This procedure may be repeated once or twice daily as necessary, for a duration of up to 2 weeks.

No additional information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)